Piechowicz Lidia, Kosznik-Kwaśnicka Katarzyna, Kaźmierczak Natalia, Grzenkowicz Milena, Stasiłojć Małgorzata, Necel Agnieszka, Werbowy Olesia, Pałubicka Anna
Department of Medical Microbiology, Faculty of Medicine, Medical University of Gdańsk, Dębowa 25, 80-204 Gdansk, Poland.
Department of Microbiology, Faculty of Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdansk, Poland.
Antibiotics (Basel). 2025 Mar 3;14(3):257. doi: 10.3390/antibiotics14030257.
The viral pandemic caused by the SARS-CoV-2 virus has affected millions of people. However, it was noticed that high mortality was often a result of bacterial co-infections. One of the main pathogens responsible for secondary infections in patients with viral respiratory tract infections, including COVID-19, is . In recent years, the number of infections caused by drug-resistant strains of has been growing rapidly, often exceeding the number of infections caused by antibiotic-sensitive strains. In addition, biofilm-related infections are more difficult to treat due to the lower sensitivity of biofilm structure to antibiotics. Bacteriophages are seen as alternative treatment of bacterial infections. Therefore, in our work, we have analyzed the efficacy of three Kayviruses against strains isolated from COVID-19 patients. We analyzed the ability of tested phages to remove biofilm both from polystyrene plates as well as from the surface of pulmonary epithelial cells. We have observed that tested Kayviruses had a broad host range. Furthermore, phages were able to effectively reduce biofilm biomass and number of viable cells in pure culture. During our research, none of the tested phages was shown to have a negative effect on cell viability and were able to inhibit the negative effect had on cell condition. Our results show tested phages were effective in reducing the biofilm of strains isolated from COVID-19 patients, had no adverse effect on lung epithelial cell viability. Therefore, it should be recognized that the properties of three studied Kayviruses give them an advantage in the selection of phages for treatment of staphylococcal infections.
由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒引起的病毒性大流行已影响数百万人。然而，人们注意到高死亡率往往是细菌合并感染的结果。在包括新型冠状病毒肺炎（COVID-19）在内的病毒性呼吸道感染患者继发性感染的主要病原体之一是 。近年来，由 耐药菌株引起的感染数量一直在迅速增长，常常超过抗生素敏感菌株引起的感染数量。此外，由于生物膜结构对抗生素的敏感性较低，与生物膜相关的感染更难治疗。噬菌体被视为细菌感染的替代治疗方法。因此，在我们的工作中，我们分析了三种凯病毒对从COVID-19患者分离出的 菌株的疗效。我们分析了受试噬菌体从聚苯乙烯平板以及肺上皮细胞表面去除 生物膜的能力。我们观察到受试凯病毒具有广泛的宿主范围。此外，噬菌体能够有效减少纯培养物中生物膜的生物量和活细胞数量。在我们的研究过程中，没有一种受试噬菌体对细胞活力有负面影响，并且能够抑制 对细胞状况的负面影响。我们的结果表明，受试噬菌体在减少从COVID-19患者分离出的 菌株的生物膜方面有效，对肺上皮细胞活力没有不利影响。因此，应该认识到三种研究的凯病毒的特性使它们在选择用于治疗葡萄球菌感染的噬菌体方面具有优势。
